Global OmeprazoleMarket, by Dosage Form (Capsule, Powder, and Tablet), by Indication(Duodenal Ulcer, Gastric Ulcer, Gastroesophageal Reflux Disease (GERD), ErosiveEsophagitis, and Others), by Distribution Channel (Hospital Pharmacies, RetailPharmacies, and Online Pharmacies), and by Region (North America, LatinAmerica, Europe, Asia Pacific, Middle East, and Africa) was valued at US$2,668.4 million in 2017, and is projected to exhibit a CAGR of 5.2% over theforecast period (2018 – 2026).
Launch of cost-effective genericsby the market players to augment the market growth The global omeprazole marketis expected to witness significant growth over the forecast period attributedto increasing incidence of gastric ulcers caused due to H.pylori infection andNonsteroidal Anti-Inflammatory Drugs (NSAID) use. According to the study byDeccan College of Medical Sciences, 2016, an estimated 95% of duodenal and 70%of gastric ulcers are attributed due to Helicobacter pylori. Furthermore, thestudy also stated that around 14-25% of gastric and duodenal ulcers areassociated with NSAID use. Furthermore, developers are focusing on approval andlaunch of cost-effective generic versions of omeprazole in order to enhancemarket sales. For instance, in July, 2017, Breckenridge Pharmaceutical, Inc.received the U.S. Food and Drug Administration (FDA) approval of abbreviatednew drug application (ANDA) for Omeprazole delayed-release capsules. The drugwill be manufactured and supplied by parent company- Laboratorios Dr. Esteve,S.A., Spain.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2380
Browse 22 Market Data Tables and24 Figures spread through 138 Pages and in-depth TOC on “Omeprazole Market”-Global Forecast to 2026, by Dosage Form (Capsule, Powder, and Tablet), by Indication(Duodenal Ulcer, Gastric Ulcer, Gastroesophageal Reflux Disease (GERD), ErosiveEsophagitis, and Others), by Distribution Channel (Hospital Pharmacies, RetailPharmacies, and Online Pharmacies), and by Region (North America, LatinAmerica, Europe, Asia Pacific, Middle East, and Africa)
Gastroesophageal reflux disease(GERD) is a chronic digestive disorder where the stomach acid enters esophagus,causing inflammation. The condition results in a long-lasting and serious fromof acid reflux. According to the National Institute of Diabetes and Digestiveand Kidney Diseases, 2014, an estimated 15.1 to 30 percent of the U.S.population is diagnosed with GERD. Moreover, According to the Department ofGastroenterology, Cedars-Sinai Medical Center, 2014, over nine million primarycare visits in the U.S. are attributed to GERD annually, making it the mostcommon gastroenterology-related outpatient diagnosis disease in the country.The market players are focused on developing treatment to offer heartburnrelief by implementing innovative technologies. For instance, in April, 2018,Perrigo Company plc. and Dexcel Pharma Technologies, Ltd., launched Omeprazoledelayed release orally disintegrating tablets (ODT) 20mg, with innovativeMelTech melt-in-your-mouth technology for treating frequent heartburn. Theinnovative technology provides an affordable option in the OTC category.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/omeprazole-market-2380
Key Takeaways of the OmeprazoleMarket:
The global omeprazole market isexpected to exhibit a CAGR of 5.2% over the forecast period, owing toincreasing prevalence of peptic ulcer and acid related diseases and approval ofgeneric versions by regulatory agencies. For instance, in 2016, Perrigo Companyplc.received the U.S. FDA approval for omeprazole, thus launching a brandequivalent to Zegerid OTC capsules. Zegerid OTC is indicated for the treatmentof frequent heartburn.
Among distribution channel, theonline pharmacy segment is expected to holds a dominant position in theomeprazole market in 2026, owing to the higher amount of discount couponsgranted for the generic and OTC omeprazole drugs
Some of the major playersoperating in the global omeprazole market include, Astrazeneca Plc., Sandoz,Inc., Mylan N.V., Apotex, Inc., Dr. Reddy’s Laboratories, Inc., ImpaxLaboratories, Inc., Perrigo Company Plc., Santarus, Inc., Watson laboratories,Inc., and Lek Pharmaceuticals d.d.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2380
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollar opportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
